H.C. Wainwright Reiterates Buy Rating on Disc Medicine (IRON)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $118.00 price target on Disc Medicine (NASDAQ: IRON).

The analyst commented: "Bitopertin is well positioned for accelerated approval, given consistent and durable efficacy; early signs of liver function improvement portend long-term benefits beyond sunlight. The positive data from the HELIOS study further bolstered our confidence in bitopertin to win accelerated approval as the first disease-modifying treatment for EPP. HELIOS is a Phase 2 open-label extension (OLE) study evaluating bitopertin in EPP patients treated in the AURORA and BEACON studies. As of the February 4 data cut-off, 86 patients received bitopertin at 60mg once daily (QD) during the OLE study. We reiterate our Buy rating and price target of $118 for Disc."

For an analyst ratings summary and ratings history on Disc Medicine click here. For more ratings news on Disc Medicine click here.

Shares of Disc Medicine closed at $52.02 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades Telecom Argentina (TEO) to Overweight
• KeyBanc Reiterates Overweight Rating on Sunbelt Rentals (SUNB)
• RBC Capital Reiterates Outperform Rating on Coursera Inc (COUR)